Antimalarial Therapeutic Strategies for Plasmodium Falciparum Infection

Plasmodium falciparum remains the most virulent malaria parasite, responsible for the majority of malaria-related mortality worldwide. Control and elimination efforts depend heavily on effective chemotherapy, centred on artemisinin-based combination therapies (ACTs) which unite a fast-acting artemisinin derivative and a longer-acting partner drug. The strategic use of ACTs has dramatically reduced disease burden, but the spread of artemisinin partial resistance in the Greater Mekong subregion and emerging partner-drug failures have exposed critical vulnerabilities. In response, research efforts have diversified across several fronts: development of novel partner drugs with distinct modes of action; optimisation of dosing regimens through pharmacokinetic–pharmacodynamic modelling; exploration of triple-combination therapies to forestall resistance; and repurposing of historically effective compounds such as pyronaridine. Parallel work targets transmission-blocking interventions, including single-dose primaquine additions to ACTs to curtail gametocyte carriage, and mass drug administration campaigns guided by safety assessments for electrocardiographic effects. Advances in analytical methods, notably polymerase chain reaction-corrected efficacy evaluations and population pharmacokinetic meta-analyses, have refined our understanding of drug exposure in vulnerable groups such as young children and pregnant women. Ultimately, integrated drug development, surveillance of molecular markers of resistance, and adaptive treatment guidelines underpin contemporary therapeutic strategies against P. falciparum.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Antimalarial Therapeutic Strategies for Plasmodium Falciparum Infection publication trend

The graph below shows the total number of articles in antimalarial therapeutic strategies for plasmodium falciparum infection across all publications each year (not limited to Nature Index journals).

Technical terms

Artemisinin-based combination therapy (ACT): A treatment strategy combining a fast-acting artemisinin derivative with a longer-acting antimalarial partner drug to enhance parasite clearance and delay resistance.

Polymerase chain reaction (PCR)-corrected cure rate: The proportion of patients free of recrudescent infection after distinguishing reinfection from treatment failure using genetic fingerprinting of parasites.

Pharmacokinetics: The study of drug absorption, distribution, metabolism and excretion that informs optimal dosing regimens across different patient groups.

Gametocyte carriage: The presence of sexual parasite stages in the bloodstream, which are responsible for transmission to mosquitoes and are targeted by transmission-blocking agents.

Recrudescence: The resurgence of malaria infection from surviving parasites after treatment, indicative of therapeutic failure rather than a new infection.

References

1. Efficacy and safety of pyronaridine–artesunate versus artemether–lumefantrine in the treatment of acute uncomplicated malaria in children in South-West Nigeria: an open-labelled randomized controlled trial. Malaria Journal (2023).
2. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis. PLOS Medicine (2017).
3. Population pharmacokinetics and electrocardiographic effects of dihydroartemisinin–piperaquine in healthy volunteers. British Journal of Clinical Pharmacology (2017).